Timothy R. Sterling

Timothy R. Sterling's AcademicInfluence.com Rankings

Timothy R. Sterling

Philosophy

#9477

World Rank

#13042

Historical Rank

Logic

#6450

World Rank

#7967

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Timothy R. Sterling's Degrees

Doctorate Medicine Harvard University

Why Is Timothy R. Sterling Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Timothy R. Sterling's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada (2013) (1190)
Effect of early versus deferred antiretroviral therapy for HIV on survival. (2009) (1170)
An official ATS statement: hepatotoxicity of antituberculosis therapy. (2006) (964)
The emergence of drug-resistant tuberculosis in New York City. (1993) (919)
Three months of rifapentine and isoniazid for latent tuberculosis infection. (2011) (772)
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies (2017) (691)
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries (2015) (477)
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. (2012) (475)
Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017) (457)
Antiretroviral Therapy for Prevention of Tuberculosis in Adults with HIV: A Systematic Review and Meta-Analysis (2012) (364)
Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. (2001) (352)
Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017) (336)
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. (2015) (240)
The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. (1996) (238)
A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. (2012) (216)
Late presentation for human immunodeficiency virus care in the United States and Canada. (2010) (215)
Latent TB infection treatment acceptance and completion in the United States and Canada. (2010) (202)
Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. (2016) (198)
Invasive Cervical Cancer Risk Among HIV-Infected Women: A North American Multicohort Collaboration Prospective Study (2013) (193)
Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020 (2020) (189)
Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection: A North American Cross Cohort Analysis (2013) (189)
Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based Regimens (2017) (187)
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). (2007) (178)
Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. (1999) (177)
Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy. (2019) (175)
Paradoxical worsening of tuberculosis in HIV-infected persons. (2001) (174)
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. (2015) (171)
Lack of weight gain and relapse risk in a large tuberculosis treatment trial. (2006) (167)
HIV infection-related tuberculosis: clinical manifestations and treatment. (2010) (158)
An internationally generalizable risk index for mortality after one year of antiretroviral therapy (2013) (148)
HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy (2001) (145)
Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. (2009) (144)
Retention Among North American HIV-Infected Persons in Clinical Care, 2000–2008 (2013) (135)
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. (2014) (134)
Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients (2014) (123)
Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. (2002) (122)
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons (2016) (119)
Tuberculosis and HIV. (2002) (118)
Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States (2018) (115)
Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. (2016) (114)
Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. (2009) (113)
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. (2006) (111)
U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected Persons, 2000 to 2008 (2012) (106)
Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada (2020) (104)
Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. (2003) (103)
Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. (2003) (99)
Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. (2004) (97)
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. (2013) (96)
Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population (2017) (94)
Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. (2007) (93)
Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. (2004) (91)
Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. (1999) (90)
Normal chest radiography in pulmonary tuberculosis: implications for obtaining respiratory specimen cultures. (2008) (89)
Transmission of Mycobacterium tuberculosis from a cadaver to an embalmer. (2000) (89)
Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. (2006) (88)
Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. (2003) (88)
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002–2009 (2012) (86)
CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation? (2010) (86)
The rapid development of fluoroquinolone resistance in M. tuberculosis. (2003) (84)
Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy (2016) (84)
Transmission of Mycobacterium tuberculosis through casual contact with an infectious case. (2001) (83)
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. (2004) (82)
Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. (2009) (78)
A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. (2002) (78)
Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis (2003) (77)
Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. (2019) (76)
The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. (2006) (76)
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. (2015) (75)
Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. (2016) (74)
Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users (2001) (74)
Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. (2007) (73)
CD4+/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy (2016) (73)
Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. (2001) (72)
Black race, sex, and extrapulmonary tuberculosis risk: an observational study (2010) (72)
Polymorphisms in IL-1β, vitamin D receptor Fok1, and Toll-like receptor 2 are associated with extrapulmonary tuberculosis (2010) (72)
Timing of Antiretroviral Therapy Initiation in Tuberculosis Patients With AIDS: A Decision Analysis (2007) (71)
An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy. (2011) (70)
Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). (2014) (68)
Diagnosis and treatment of ventilator-associated pneumonia--impact on survival. A decision analysis. (1996) (68)
Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. (2019) (68)
Tuberculosis and cardiovascular disease: linking the epidemics (2015) (65)
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. (2009) (64)
Serum albumin as a prognostic indicator for HIV disease progression. (2006) (64)
Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting (2011) (63)
Disparities in the quality of HIV care when using US Department of Health and Human Services indicators. (2014) (62)
CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. (2005) (62)
Resistance to amphotericin B: emerging clinical and microbiological patterns. (1998) (62)
Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. (2013) (61)
Tuberculosis (1925) (61)
RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response (2020) (61)
CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC) (2017) (61)
CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC) (2017) (61)
Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America (2017) (59)
A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. (2002) (59)
High Proportion of Heteroresistance in gyrA and gyrB in Fluoroquinolone-Resistant Mycobacterium tuberculosis Clinical Isolates (2014) (57)
Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. (2015) (54)
A multi-state outbreak of tuberculosis among members of a highly mobile social network: implications for tuberculosis elimination. (2000) (53)
Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin- Mono-Resistant Pulmonary Tuberculosis in Lima, Peru (2016) (53)
Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. (2005) (53)
Tuberculosis Meningitis (2017) (52)
Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity. (2003) (52)
Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study (2016) (51)
Increased Frequency of Regulatory T Cells and T Lymphocyte Activation in Persons with Previously Treated Extrapulmonary Tuberculosis (2011) (51)
Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. (2013) (50)
Sex differences in HIV outcomes in the highly active antiretroviral therapy era: a systematic review. (2014) (50)
Human immunodeficiency virus-seronegative adults with extrapulmonary tuberculosis have abnormal innate immune responses. (2001) (49)
Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy. (2013) (48)
Geographic Variations in Retention in Care among HIV-Infected Adults in the United States (2016) (47)
Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. (2009) (46)
Risk and Timing of Tuberculosis Among Close Contacts of Persons with Infectious Tuberculosis (2018) (46)
High Proportion of Fluoroquinolone-Resistant Mycobacterium tuberculosis Isolates with Novel Gyrase Polymorphisms and a gyrA Region Associated with Fluoroquinolone Susceptibility (2011) (46)
Risk and Timing of Tuberculosis Among Close Contacts of Persons with Infectious Tuberculosis (2018) (46)
Drug Use and Receipt of Highly Active Antiretroviral Therapy among HIV-Infected Persons in Two U.S. Clinic Cohorts (2011) (46)
Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements (2009) (44)
The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy (2015) (43)
Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV (2018) (43)
Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada (2017) (42)
Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials (2018) (42)
Impact of empiric antibiotics and chest radiograph on delays in the diagnosis of tuberculosis. (2005) (41)
Risk factors for treatment default in close contacts with latent tuberculous infection. (2014) (41)
Tuberculosis and risk of acute myocardial infarction: a propensity score-matched analysis (2017) (40)
Transmission of Mycobacterium tuberculosis from health care workers. (2006) (40)
Extensively drug-resistant tuberculosis: are we learning from history or repeating it? (2007) (38)
Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada. (2016) (38)
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. (2019) (38)
Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration (2015) (38)
Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. (2011) (38)
The Relationship Between Latent Tuberculosis Infection and Acute Myocardial Infarction (2018) (37)
HIV-related tuberculosis in a transgender network--Baltimore, Maryland, and New York City area, 1998-2000. (2000) (36)
Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection. (2014) (36)
Decreased CD4+ lymphocytes and innate immune responses in adults with previous extrapulmonary tuberculosis. (2006) (36)
RePORT International: Advancing Tuberculosis Biomarker Research Through Global Collaboration. (2015) (36)
The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls. (2004) (36)
Chronic lung disease and HIV infection are risk factors for recurrent tuberculosis in a low-incidence setting. (2011) (35)
Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada (2017) (34)
Higher Time-Updated Body Mass Index: Association With Improved CD4+ Cell Recovery on HIV Treatment (2016) (34)
Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host. (1996) (34)
Differential expression of activation markers by Mycobacterium tuberculosis-specific CD4+ T-cell distinguishes extrapulmonary from pulmonary tuberculosis and latent infection. (2019) (33)
Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study (2017) (33)
Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study (2017) (33)
The VACS Index (2013) (32)
Novel human genetic variants associated with extrapulmonary tuberculosis: a pilot genome wide association study (2011) (31)
Heat-denatured human immunodeficiency virus type 1 protein 24 antigen: prognostic value in adults with early-stage disease. (2002) (31)
Increased non‐AIDS mortality among persons with AIDS‐defining events after antiretroviral therapy initiation (2018) (31)
Risk of Incident Diabetes Mellitus, Weight Gain, and their Relationships with Integrase Inhibitor-based Initial Antiretroviral Therapy Among Persons with HIV in the US and Canada. (2020) (31)
Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe, and the United States. (2013) (31)
Active cocaine use is associated with lack of HIV-1 virologic suppression independent of nonadherence to antiretroviral therapy: Use of a rapid screening tool during routine clinic visits (2013) (30)
New approaches to the treatment of latent tuberculosis. (2008) (29)
Treatment of Latent Tuberculosis Infection-An Update. (2019) (29)
Agreement of decision analyses and subsequent clinical studies in infectious diseases. (2007) (29)
HIV and cancer: a comparative retrospective study of Brazilian and U.S. clinical cohorts (2015) (28)
Association between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001–2009 (2013) (27)
251 – Mycobacterium tuberculosis (2015) (27)
Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. (2007) (26)
Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries (2016) (25)
Immune Function in Young Children With Previous Pulmonary or Miliary/Meningeal Tuberculosis and Impact of BCG Vaccination (2007) (25)
Health Literacy and Demographic Disparities in HIV Care Continuum Outcomes (2018) (25)
Daily Marijuana Use is Associated with Missed Clinic Appointments Among HIV-Infected Persons Engaged in HIV Care (2017) (25)
Evaluation of an extensive tuberculosis contact investigation in an urban community and jail. (2003) (24)
Tuberculosis in Antiretroviral Treatment Programs in Lower Income Countries: Availability and Use of Diagnostics and Screening (2013) (23)
Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model (2019) (23)
Antiretroviral Therapy Initiation Before, During, or After Pregnancy in HIV-1-Infected Women: Maternal Virologic, Immunologic, and Clinical Response (2009) (23)
Prescribing of Contraindicated Protease Inhibitor and Statin Combinations Among HIV-Infected Persons (2005) (23)
Race, kidney disease progression, and mortality risk in HIV-infected persons. (2010) (23)
Prognostic Factors for Survival Differ According to CD4+ Cell Count Among HIV-Infected Injection Drug Users: Pre-HAART and HAART Eras (2005) (22)
HIV-1 Transmission Clustering and Phylodynamics Highlight the Important Role of Young Men Who Have Sex with Men (2018) (22)
Use of DNA Fingerprinting To Investigate a Multiyear, Multistate Tuberculosis Outbreak (2002) (22)
Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa. (2017) (22)
Abnormal Immune Responses in Persons with Previous Extrapulmonary Tuberculosis in an In Vitro Model That Simulates In Vivo Infection with Mycobacterium tuberculosis (2012) (22)
Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected Adults in North America. (2015) (22)
HIV in the workplace in Botswana: incidence, prevalence, and disease severity. (2007) (21)
Sex Differences in Overall and Cause-Specific Mortality among HIV-Infected Adults on Antiretroviral Therapy in Europe, Canada and the US (2015) (21)
The relationship between adverse neighborhood socioeconomic context and HIV continuum of care outcomes in a diverse HIV clinic cohort in the Southern United States (2018) (20)
Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. (2013) (20)
Risk Factors for Tuberculosis and Effect of Preventive Therapy Among Close Contacts of Persons with Infectious Tuberculosis. (2019) (20)
Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States. (2010) (20)
Diagnosis and treatment of latent tuberculosis infection: an update (2013) (19)
Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. (2013) (19)
Efavirenz Pharmacogenetics and Weight Gain following Switch to Integrase Inhibitor-containing Regimens. (2020) (19)
Outcomes of HIV-positive patients with cryptococcal meningitis in the Americas. (2017) (18)
General Clinical Manifestations of Human Immunodeficiency Virus Infection (Including Acute Retroviral Syndrome and Oral, Cutaneous, Renal, Ocular, Metabolic, and Cardiac Diseases) (2015) (18)
Increased vitamin D receptor expression from macrophages after stimulation with M. tuberculosis among persons who have recovered from extrapulmonary tuberculosis (2019) (18)
Stability of antituberculosis drugs mixed in food. (2007) (18)
Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures. (2008) (18)
Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020 (2020) (17)
The relationship between injection and noninjection drug use and HIV disease progression. (2011) (17)
Reversible Posterior Leukoencephalopathy in an HIV-infected Patient with Thrombotic Thrombocytopenic Purpura (2002) (17)
Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in low‐ and middle‐income countries: a multicohort study (2019) (17)
Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients (2019) (16)
Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1–Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy (2018) (16)
Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015 (2021) (16)
Tuberculosis Risk Before and After Highly Active Antiretroviral Therapy Initiation: Does HAART Increase the Short-Term TB Risk in a Low Incidence TB Setting? (2011) (16)
Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults (2021) (16)
Treatment of latent tuberculosis infection: challenges and prospects. (2005) (16)
Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities. (2017) (15)
Latent Tuberculosis Infection and Subclinical Coronary Atherosclerosis in Peru and Uganda. (2021) (15)
Risk of HCC With Hepatitis B Viremia Among HIV/HBV‐Coinfected Persons in North America (2021) (15)
Treatment of Latent Tuberculosis Infection in HIV: Shorter or Longer? (2012) (15)
Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis (2013) (15)
Identification of Mycobacterium tuberculosis Peptides in Serum Extracellular Vesicles from Persons with Latent Tuberculosis Infection (2020) (14)
Isoniazid preventive therapy in areas of high isoniazid resistance. (1995) (14)
Sex-based differences in T lymphocyte responses in HIV-1-seropositive individuals. (2005) (14)
Estimating the Optimal CD4 Count for HIV-infected Persons to Start Antiretroviral Therapy (2010) (14)
Latent tuberculosis infection is associated with increased unstimulated levels of interferon-gamma in Lima, Peru (2018) (13)
Hemoglobin May Contribute to Sex Differences in Mortality among HIV-Infected Persons in Care (2012) (13)
Novel stepwise approach to assess representativeness of a large multicenter observational cohort of tuberculosis patients: The example of RePORT Brazil (2020) (13)
Duration of Exposure Among Close Contacts of Patients With Infectious Tuberculosis and Risk of Latent Tuberculosis Infection. (2020) (13)
ACCOUNTING FOR DEPENDENT ERRORS IN PREDICTORS AND TIME-TO-EVENT OUTCOMES USING ELECTRONIC HEALTH RECORDS, VALIDATION SAMPLES, AND MULTIPLE IMPUTATION. (2020) (12)
Current drug use and lack of HIV virologic suppression: point-of-care urine drug screen versus self-report (2014) (12)
Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america. (2011) (12)
Non-adherence and drug-related interruptions are risk factors for delays in completion of treatment for tuberculosis. (2013) (12)
Accuracy of pharmacy and coded‐diagnosis information in identifying tuberculosis in patients with rheumatoid arthritis (2012) (11)
Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis. (2016) (11)
Pharmacokinetics and Drug‐Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping (2020) (11)
CD4/CD8 ratio and CD4 nadir predict mortality following non-communicable disease diagnosis in adults living with HIV. (2019) (11)
A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis. (2016) (11)
One Size Fits (n)One: The Influence of Sex, Age, and Sexual Human Immunodeficiency Virus (HIV) Acquisition Risk on Racial/Ethnic Disparities in the HIV Care Continuum in the United States (2018) (11)
Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death. (2012) (11)
Polymorphisms in TLR4 and TNFA and Risk of Mycobacterium tuberculosis Infection and Development of Active Disease in Contacts of Tuberculosis Cases in Brazil: A Prospective Cohort Study. (2018) (11)
Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study. (2013) (10)
Fluoroquinolone Exposure Prior To Tuberculosis Diagnosis Is Associated With An Increased Risk Of Death (2011) (10)
Polymorphisms in interferon pathway genes and risk of Mycobacterium tuberculosis infection in contacts of tuberculosis cases in Brazil (2019) (10)
Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world. (1999) (10)
Superior Glucose Tolerance and Metabolomic Profiles, Independent of Adiposity, in HIV-Infected Women Compared With Men on Antiretroviral Therapy (2016) (10)
Increased Mortality after Tuberculosis Treatment Completion in Persons with HIV in Latin America. (2020) (10)
Mycobacterium tuberculosis infection and disease are not associated with protection against subsequent disseminated M. avium complex disease (1998) (10)
25-Hydroxyvitamin D levels after recovery from tuberculosis: insights into pathogenesis. (2014) (9)
Sociodemographic factors predict early discontinuation of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors. (2008) (9)
Hospitalization Rates and Causes among Persons with HIV in the US and Canada, 2005-2015. (2020) (9)
Health outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South America (2016) (9)
Detection and management of drug-resistant tuberculosis in HIV-infected patients in lower-income countries. (2014) (9)
Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators. (2009) (9)
HIV-related tuberculosis: mortality risk in persons without vs. with culture-confirmed disease. (2019) (9)
Hospitalization Rates and Causes among Persons with HIV in the US and Canada, 2005-2015. (2020) (9)
CD 4 : CD 8 Ratio and CD 8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy : The Antiretroviral Therapy Cohort Collaboration ( ARTCC ) (2017) (9)
Tuberculosis Burden and Determinants of Treatment Outcomes According to Age in Brazil: A Nationwide Study of 896,314 Cases Reported Between 2010 and 2019 (2021) (9)
Cumulative Incidence of Cancer among HIV-infected Individuals in North America (2016) (9)
Timing of Antiretroviral Therapy Initiation and Risk of Cancer among Persons Living with HIV. (2020) (8)
Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial. (2017) (8)
Treatment of Mycobacterium tuberculosis Infection: Time to Get a Move On? (2014) (8)
Drug-resistant tuberculosis in New York City: lessons to remember. (2006) (8)
Mortality Among Persons Entering HIV Care Compared With the General U.S. Population (2021) (8)
Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment (2016) (8)
Risk factors for treatment default in close contacts with latent tuberculosis infection (2014) (7)
The Effect of Diabetes and Prediabetes on Mycobacterium tuberculosis Transmission to Close Contacts. (2021) (7)
Determinants of losses in the latent tuberculosis infection cascade of care in Brazil (2021) (7)
Evaluation of an extensive tuberculosis contact investigation in an urban community and jail. (2003) (7)
Management of latent tuberculosis infection in immigrants. (2003) (7)
Increased Neutrophil Count and Decreased Neutrophil CD15 Expression Correlate With TB Disease Severity and Treatment Response Irrespective of HIV Co-infection (2020) (7)
A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NA-ACCORD and CCASAnet clinical cohorts (2016) (7)
Tuberculosis and the risk of infection with other intracellular bacteria: a population-based study (2014) (7)
LB9. The Effect of Initiating Integrase Inhibitor-based vs. Non-Nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy on Progression to Diabetes among North American Persons in HIV Care (2019) (6)
Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment (2022) (6)
Duration of Anti-Tuberculosis Therapy and Timing of Antiretroviral Therapy Initiation: Association with Mortality in HIV-Related Tuberculosis (2013) (6)
Self-reported Cannabis Use and Changes in Body Mass Index, CD4 T-Cell Counts, and HIV-1 RNA Suppression in Treated Persons with HIV (2019) (6)
Early Retention in Care Neither Mediates Nor Modifies the Effect of Sex and Sexual Mode of HIV Acquisition on HIV Survival in the Americas (2018) (6)
Long-term trends in CD4 cell counts, CD8 cell counts, and the CD4: CD8 ratio: ART Cohort Collaboration (ART-CC) Study. (2018) (6)
Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. (2019) (6)
Tuberculosis in a neighborhood bar. (1996) (5)
Optimal testing choice and diagnostic strategies for latent tuberculosis infection among U.S.-born people living with HIV. (2020) (5)
Potentially preventable tuberculosis among HIV-infected persons in the era of highly active antiretroviral treatment. (2009) (4)
Predictive value of TNF-α, IFN-γ, and IL-10 for tuberculosis among recently exposed contacts in the United States and Canada (2020) (4)
Virologic, Immunologic and Clinical Responses in Foreign-Born versus US-Born HIV-1 Infected Adults Initiating Antiretroviral Therapy: An Observational Cohort Study (2012) (4)
Predictive value of TNF-α, IFN-γ, and IL-10 for tuberculosis among recently exposed contacts in the United States and Canada (2020) (4)
Resistance-conferring mutations on whole-genome sequencing of fluoroquinolone-resistant and -susceptible M. tuberculosis isolates: a proposed threshold for identifying resistance. (2020) (4)
Knowledge and stigma of latent tuberculosis infection in Brazil: implications for tuberculosis prevention strategies (2020) (4)
Clinical effectiveness of integrase strand transfer inhibitor-based antiretroviral regimens among adults with human immunodeficiency virus: a collaboration of cohort studies in the United States and Canada. (2020) (4)
Diagnostic biomarkers for active tuberculosis: progress and challenges (2022) (4)
ODELAM, rapid sequence-independent detection of drug resistance in isolates of Mycobacterium tuberculosis (2020) (4)
' s response to reviews Title : Polymorphisms in IL-1 beta , Vitamin D Receptor Fok 1 , and Toll-like Receptor 2 Are Associated with Extrapulmonary Tuberculosis (2009) (4)
' s response to reviews Title : Polymorphisms in IL-1 beta , Vitamin D Receptor Fok 1 , and Toll-like Receptor 2 Are Associated with Extrapulmonary Tuberculosis (2009) (4)
Comparing results from multiple imputation and dynamic marginal structural models for estimating when to start antiretroviral therapy (2016) (4)
RISK6, a universal 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response (2019) (4)
Abnormal Immune Responses In Persons With Previous Extrapulmonary Tuberculosis In An In Vitro Macrophage Model That Simulates In Vivo Infection With M. Tuberculosis (2010) (3)
Antiretroviral therapy: when to start & what to start with. (2002) (3)
Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study (2021) (3)
Mood Disorders and Increased Risk of Noncommunicable Disease in Adults With HIV. (2020) (3)
Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study (2021) (3)
Abnormal spontaneous interleukin 8 receptor expression: a brief report of two cases. (2012) (3)
Polymorphisms in TLR 4 and TNFA and Risk of Mycobacterium tuberculosis Infection and Development of Active Disease in Contacts of Tuberculosis Cases in Brazil : A Prospective Cohort Study (2018) (3)
Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy (2021) (3)
Older age at first tuberculosis diagnosis is associated with tuberculosis recurrence in HIV-negative persons. (2018) (3)
CD4 count at entry into HIV care and at antiretroviral therapy prescription in the US, 2005-2018. (2020) (3)
HIV and paradoxical worsening of tuberculosis. (2001) (3)
Treatment of drug-susceptible tuberculosis among people living with human immunodeficiency virus infection: an update (2018) (3)
Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV (2021) (3)
Effects of Pregnancy and Isoniazid Preventive Therapy on M. tuberculosis Interferon Gamma Response Assays in Women with HIV. (2020) (2)
Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. (2023) (2)
Are we ready to shorten the treatment duration for non-cavitary pulmonary tuberculosis? (2013) (2)
When should highly active antiretroviral therapy be initiated? (2001) (2)
Lack of weight gain during the first two months of treatment and HIV independently predict unsuccessful treatment outcomes in tuberculosis. (2019) (2)
Mood disorders and increased risk of non-communicable disease in adults with HIV. (2020) (2)
Increased Frequency of Memory CD4+ T-Cell Responses in Individuals With Previously Treated Extrapulmonary Tuberculosis (2020) (2)
A comparison of interview methods to ascertain fluoroquinolone exposure before tuberculosis diagnosis (2014) (2)
When to start HAART: still a controversy. Report from Seattle: the 9th Conference on Retroviruses and Opportunistic Infections (CROI). (2002) (2)
The Effect of Diabetes and Prediabetes on Anti-tuberculosis Treatment Outcomes: A Multi-center Prospective Cohort Study. (2021) (2)
Mortality Among People With HIV Treated for Tuberculosis Based on Positive, Negative, or No Bacteriologic Test Results for Tuberculosis: The IeDEA Consortium (2020) (2)
CD4/CD8 Ratio and Cancer Risk among Adults with HIV. (2022) (2)
Hepatitis C Virus Infection And Female Sex Are Risk Factors For Treatment Limiting Hepatotoxicity In A Large Clinical Trial Of Treatment Of Latent Tuberculosis Infection: Results Of A Nested Case-Control Study (2011) (2)
Treatment of latent M. tuberculosis infection and use of antiretroviral therapy to prevent tuberculosis. (2020) (2)
Trends and Disparities in Mortality and Progression to AIDS in the Highly Active Antiretroviral Therapy Era: Tennessee, 1996-2016. (2019) (2)
Hepatitis C Co-infection and Mortality in People Living with HIV in Middle Tennessee. (2019) (2)
Chronic kidney disease at presentation is not an independent risk factor for AIDS-defining events or death in HIV-infected persons (2012) (2)
Mutations In Genes For Efflux Pumps And Pentapeptide Repeat Proteins Are Associated With Fluoroquinolone Resistance In Mycobacterium Tuberculosis (2012) (2)
High mortality among patients hospitalized for drug‐resistant tuberculosis with acquired second‐line drug resistance and high HIV prevalence (2022) (2)
When to start HAART, and what to start. (2003) (2)
Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. (2021) (2)
Mortality for adults entering HIV care under universal early treatment compared to the general US population. (2022) (1)
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. (2023) (1)
Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large in (2020) (1)
High Proportion of Fluoroquinolone-Resistant Mycobacterium tuberculosis Isolates with Novel Gyrase Polymorphisms and a gyrA Region Associated with Fluoroquinolone Susceptibility (2012) (1)
The need for randomised controlled trials of isoniazid monoresistant tuberculosis treatment. (2017) (1)
Misdiagnosis of HIV infection: implications for universal testing. (2008) (1)
Determinants of losses in the tuberculosis infection cascade of care among children and adolescent contacts of pulmonary tuberculosis cases: A Brazilian multi-centre longitudinal study (2022) (1)
Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru (2021) (1)
Directly observed therapy and risk of unfavourable tuberculosis treatment outcomes among an international cohort of people living with HIV in low‐ and middle‐income countries (2019) (1)
Using a composite maternal-infant outcome measure in tuberculosis prevention studies among pregnant women. (2020) (1)
CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018 (2020) (1)
CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018 (2020) (1)
Differentially culturable tubercle bacteria as a measure of tuberculosis treatment response (2023) (1)
ODELAM: Rapid sequence-independent detection of drug resistance in clinical isolates of Mycobacterium tuberculosis (2020) (1)
Microcolonies in fluoroquinolone agar proportion susceptibility testing of Mycobacterium tuberculosis: an indicator of drug resistance (2012) (1)
Association of Race and Ethnicity With Initial Prescription of Antiretroviral Therapy Among People With HIV in the US. (2023) (1)
Lessons Learned from Implementation of an Interferon Gamma Release Assay to Screen for Latent Tuberculosis Infection in a Large Multicenter Observational Cohort Study in Brazil (2021) (1)
1605Active Marijuana Use Was Not Associated with Changes in Body Mass Index or CD4 T-Cell Countsi n HIV-Infected Patients (2014) (1)
Current and Past Immunodeficiency are Associated with Higher Hospitalization Rates among Persons on Virologically Suppressive Antiretroviral Therapy for up to Eleven Years. (2020) (1)
Preterm labor in pregnancies complicated by HIV (2006) (1)
Current and Past Immunodeficiency are Associated with Higher Hospitalization Rates among Persons on Virologically Suppressive Antiretroviral Therapy for up to Eleven Years. (2020) (1)
Do contemporary antiretrovirals increase the risk of end-stage liver disease? Signals from patients starting therapy in the NA-ACCORD. (2021) (1)
Prevalence and Clinical Profiling of Dysglycemia and HIV Infection in Persons With Pulmonary Tuberculosis in Brazil (2021) (1)
A Systematic Review Of Gyrase Mutations Associated With Fluoroquinolone-Resistant Mycobacterium Tuberculosis And A Proposed Gyrase Numbering System (2012) (1)
Highlights from the American Thoracic Society International Conference, May 2001. (2001) (1)
A clinical prediction model for unsuccessful pulmonary tuberculosis treatment outcomes. (2021) (1)
Lessons learned from implementation of interferon-gamma release assay to screen for latent tuberculosis infection in a large multicenter observational cohort study in Brazil (2021) (1)
Are we ready to shorten the treatment duration for non-cavitary pulmonary tuberculosis? [Editorial]. (2013) (1)
Track C Epidemiology and Prevention Science (2012) (1)
Low CD4/CD8 ratio predicts cancer risk among adults with HIV (2021) (1)
Prevalence and clinical characteristics of pulmonary TB among pregnant and post-partum women. (2022) (1)
Response to "optimum time to initiate antiretroviral therapy in patients with HIV-associated tuberculosis (2007) (1)
Reversion of phenotypic fluoroquinolone resistance in Mycobacterium tuberculosis. (2016) (1)
Weight Gain After Switch from Efavirenz-Based to Integrase Inhibitor-Based Regimens (2017) (1)
WHEN TO INITIATE HAART, HIV DISEASE PROGRESSION ACCORDING TO CD4 1EVEL AT INITIATION OF THERAPY AMONG PERSONS WITH DURABLEVIROLOGIC SUPPRESSION (2002) (1)
Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study (2022) (1)
The Effect of Diabetes and Prediabetes on Anti-tuberculosis Treatment Outcomes: A Multicentric Prospective Cohort Study (2021) (1)
Factors associated with screening failure and study withdrawal in multidrug-resistant TB. (2022) (0)
Microcolonies in fluoroquinolone agar proportion susceptibility testing of Mycobacterium tuberculosis: an indicator of drug resistance (2012) (0)
Tuberculosis treatment intermittency in the continuation phase and mortality in HIV-positive persons receiving antiretroviral therapy (2022) (0)
1387. Women Living with HIV (WLWH) Lose IFNγ Responses Diagnostic of Latent TB Infection (LTBI) during Pregnancy and after INH Prophylactic Treatment (IPT) (2019) (0)
Tuberculosis Burden and Determinants of Treatment Outcomes According to Age in Brazil: A Nationwide Ecological Study of 896,314 Cases Reported between 2010 and 2019 (2021) (0)
TUPDC0103: Gonorrhea infections diagnosed among persons living with HIV: cross matching surveillance registries to identify potential opportunities for integrated partner services-New York City, Washington D.C., Miami/Dade County and Arizona (2012) (0)
Validity of Self-Reported CD4+ Count Among HIV-infected Persons in Care (2015) (0)
Reply to: "Rifapentine and Isoniazid for Latent Tuberculosis" (2012) (0)
Track B Clinical Science (2012) (0)
Analysis of HIV/Hepatitis C Virus (HCV) Coinfection and Mortality Across Cohorts of HIV+ Patients in Middle Tennessee (2016) (0)
Recurrent Tuberculosis Risk in Tennessee, 2000-2007. (2009) (0)
TB TREATMENT OUTCOMES IN BRAZIL: DIFFERENT PREDICTORS FOR EACH TYPE OF UNSUCCESSFUL OUTCOME. (2022) (0)
Elevated Plasma Matrix Metalloproteinase 8 Associates With Sputum Culture Positivity in Pulmonary Tuberculosis (2021) (0)
Toward Ending the HIV Epidemic: Temporal Trends and Disparities in Early ART Initiation and Early Viral Suppression Among People Newly Entering HIV Care in the United States, 2012-2018. (2022) (0)
4298 Prediction models for pulmonary tuberculosis treatment outcomes: a systematic review (2020) (0)
Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru (2021) (0)
Title: ODELAM: Rapid sequence-independent detection of drug resistance in clinical isolates of Mycobacterium tuberculosis (2021) (0)
Benefits of Isoniazid Preventive Therapy-Reply (1996) (0)
CD4:CD8 ratio and CD8 count as prognostic markers for mortality in HIV-positive patients on ART (2017) (0)
A Systematic Review of Prediction Models for Tuberculosis Treatment Outcomes (2020) (0)
Previously Treated TB Patients Have A Higher Percentage Of Circulating Treg CD4+CD25highFoxP3 CD127- Cells Than Persons With Latent M. Tuberculosis Infection (2010) (0)
RNA editing in Mycobacterium tuberculosis. (2022) (0)
Secular Trends in Breast Cancer Risk Among Women With HIV Initiating ART in North America (2021) (0)
Mycobacterium tuberculosis gene expression associated with fluoroquinolone resistance and efflux pump inhibition. (2023) (0)
Sex and Race Disparities in Mortality and Years of Potential Life Lost Among People With HIV: A 21-Year Observational Cohort Study (2022) (0)
Prediction models for pulmonary tuberculosis treatment outcomes: a systematic review (2020) (0)
Re-evaluation of a novel resistance mutation in eccC5 of the ESX-5 secretion system in ofloxacin-resistant Mycobacterium tuberculosis. (2020) (0)
Determinants of Losses in the Tuberculosis Infection Cascade of Care Among Children and Adolescent Contacts of Pulmonary Tuberculosis Cases in Brazil (2022) (0)
Hormonal Contraception and Risk of Psychiatric and Other Noncommunicable Diseases in HIV-Infected Women. (2015) (0)
1135High rates of self-reported alcohol use in HIV/HCV co-infected and HIV mono-infected patients in a Southeastern U.S. Cohort (2014) (0)
Recent Advances in the Treatment of Latent Tuberculosis Infection Among Adults Living with HIV Infection (2019) (0)
Hot Topic – Latente Tuberkulose-Infektion: 12-wöchige Therapie mit Rifapentin und Isoniazid zur Prävention ab 2 Jahren von der FDA zugelassen (2015) (0)
Contributors (2015) (0)
19th International Workshop on HIV Observation Databases, Catania, Italy (2015) (0)
Low Rates of Contraception Use in Women With Human Immunodeficiency Virus (2022) (0)
Visualizing the Geography of HIV Observational Cohorts With Density-Adjusted Cartograms (2021) (0)
Stability of Antituberculosis Drugs Mixed in Food. Authors' reply (2007) (0)
Anemia and anti-tuberculosis treatment outcome in persons with pulmonary tuberculosis: A multi-center prospective cohort study. (2023) (0)
Selected topics from the 38th annual meeting of the Infectious Diseases Society of America, September 7-10, 2000, New Orleans, Louisiana and selected topics from the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Ontario, Canada. (2001) (0)
Effect of Dysglycemia on Urinary Lipid Mediator Profiles in Persons With Pulmonary Tuberculosis (2022) (0)
2008 Spring Symposium on Global Health Research - April 2, 2008 (2008) (0)
Report from the 38th IDSA: tuberculosis & HIV. (2000) (0)
Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine. (2023) (0)
THE AUTHORS AND A COLLEAGUE REPLY (2019) (0)
Current Issues in TB/HIV (2005) (0)
Treatment of tuberculosis in the HIV-infected patient. (2003) (0)
Effect of pregnancy versus postpartum maternal isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants: a post-hoc analysis of the TB APPRISE trial (2023) (0)
HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico (2015) (0)
Adherence to antiretroviral therapy. (2001) (0)
1648. CD4 T Lymphocyte and Monocyte Activation within One Year After Treatment Completion for Pulmonary Tuberculosis: A Pilot Study (2020) (0)
Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa (2023) (0)
2300 Association between source case cavitation on chest radiograph and QuantiFERON-TB Gold In-Tube conversion among close contacts of active tuberculosis cases in Brazil (2018) (0)
Risk Factors for Missed Study Visits Among Patients with a Positive Screening Test for Latent Tuberculosis Infection (LTBI) (2016) (0)
RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response (2020) (0)
Risk Factors For Treatment Default And Risk Of Tuberculosis In Close Contacts With Latent Mycobacterium Tuberculosis Infection Treated With Isoniazid (2012) (0)
Breakout Groups to Discuss Cases : Issues in HIV/TB Co-Infection (2004) (0)
Evaluating the Cardiovascular Risk in an Aging Population of People With HIV: The Impact of Hepatitis C Virus Coinfection (2022) (0)
Evolving trends in causes of death among treated HIV-positive individuals (2015) (0)
O122: Managing tuberculosis and HIV (2015) (0)
Response to: A Brazilian Experience in Response to Optimum Time to Initiate Antiretroviral Therapy in Patients With HIV-Associated Tuberculosis (2009) (0)
Latent Tuberculosis Infection-Advances and Challenges (2017) (0)
When to start therapy. Authors' reply (2005) (0)
The Cost-Effectiveness Of 3 Months Of Weekly, Directly-Observed Rifapentine Plus Isoniazid (3HP) Vs. 9 Months Of Daily, Self-Administered Isoniazid (9H) For The Treatment Of Latent Tuberculosis Infection (2012) (0)
Corrigendum to: Clinical Effectiveness of Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada. (2022) (0)
Tuberculosis Increases Long-Term Risk of Mortality due to non-AIDS defining events (NADEs) among HIV-infected persons on Antiretroviral Therapy (ART) (2015) (0)
Representativeness of a Large Multicenter Observational Cohort of Tuberculosis Patients: The Example of RePORT Brazil (2020) (0)
ours and in the previously mentioned settings where the possibility of resistance to polyene antibiotics is increased. (1996) (0)
Opportunistic infections. (2000) (0)
Snapshot from Durban: initiation of antiretroviral therapy. (2000) (0)
Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection (2020) (0)
Reply to Phillips and Lampe (2005) (0)
Fluoroquinolone Susceptibility Testing inM. tuberculosis: Comparison of Nitrate Reductase Assay and Agar Proportion Method. (2009) (0)
Reply to Westreich and Kipp and to Chen et al (2008) (0)
High alcohol use is associated with non-AIDS-related mortality in the ART-CC (2015) (0)
Possible sex difference in latent tuberculosis infection risk among close tuberculosis contacts (2022) (0)
3166 Association between HIV and early weight loss and the impact on subsequent treatment outcomes among patients with tuberculosis (2019) (0)
Isoniazid Preventive Therapy-Reply (1996) (0)
Mycobacterium Tuberculosis Infection Among Child and Adolescent Contacts of Pulmonary Tuberculosis Cases in Brazil: A Multi-Center Prospective Cohort Study (2022) (0)
Mortality declined substantially between 1996-2010 among patients starting ART (2015) (0)
Pregnancy and HIV disease progression in the era of highly active antiretroviral therapy (HAART) (2005) (0)
Low rates of contraception use in women with HIV (2022) (0)
Re: MDR-TB: DOTS-plus strengthens, not weakens DOTS (2017) (0)
Systematic Review Contact Investigation and Preventive Therapy as Tuberculosis prevention in Children with Tuberculosis Household Contact: A Systematic Review (2020) (0)
Hypersensitivity reactions among persons receiving a 3 month regimen of rifapentine plus isoniazid for treatment of latent tuberculosis infection (LTBI) (2013) (0)
Tuberculosis Treatment Completion In Tennessee (2012) (0)
Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV (2021) (0)
Mortality among adults living with HIV treated for tuberculosis based on positive, negative, or no bacteriologic test results for tuberculosis: the IeDEA consortium (2019) (0)
Author response: ODELAM, rapid sequence-independent detection of drug resistance in isolates of Mycobacterium tuberculosis (2020) (0)
Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment (2015) (0)
Snapshot from Durban: new antiretroviral agents. (2000) (0)
Tuberculosis: Update on Diagnosis and Therapy (2007) (0)
The impact of M. tuberculosis infection on subsequent disseminated MAC disease in KV-infected persons (1997) (0)
Impact of DOTS and DOTS-plus on multidrug resistant TB: Authors' reply (2003) (0)
Infant birth weight in pregnancies complicated by HIV infection (2006) (0)
Tuberculosis treatment outcomes of diabetic and non-diabetic TB/HIV co-infected patients: A nationwide observational study in Brazil (2022) (0)
Whole Blood Assay for a Broad Assessment of Human Immune Responses toMycobacterium tuberculosisAntigens. (2009) (0)
Reply to Amendola et al. (2009) (0)
HIV and cancer: a comparative retrospective study of Brazilian and U.S. clinical cohorts (2015) (0)
HIV-1 infection in women. (2000) (0)
Late-onset opportunistic infections while receiving anti-retroviral therapy in Latin America: burden and risk factors (2022) (0)
Breakout: TB and HIV Co-infection (2006) (0)
Immunologic Biomarkers in Peripheral Blood of Persons With Tuberculosis and Advanced HIV (2022) (0)
Tuberculosis treatment intermittency in the continuation phase and mortality in HIV-positive persons receiving antiretroviral therapy (2022) (0)
53. Sex and Race Disparities in Premature Mortality among People with HIV: A 21-Year Observational Cohort Study (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Timothy R. Sterling?

Timothy R. Sterling is affiliated with the following schools:

Simon Fraser University
Vanderbilt University
University of California, San Francisco
Massachusetts General Hospital
Harvard University